Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

20141,057 citationsJournal Articlebronze Open Access

Authors

Loı̈c Guillevin · Sorbonne Paris Cité

Christian Pagnoux · Inserm

Alexandre Karras · Hôpital Européen Georges-Pompidou

C. Khouatra · Hôpital Louis Pradel

O. Aumaître · Centre Hospitalier Universitaire de Clermont-Ferrand

Pascal Cohen · Inserm

F. Maurier

Abstract

More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine. (Funded by the French Ministry of Health; MAINRITSAN ClinicalTrials.gov number, NCT00748644; EudraCT number, 2008-002846-51.).

Topics & Keywords

Vasculitis and related conditions Coagulation, Bradykinin, Polyphosphates, and Angioedema Renal Diseases and Glomerulopathies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 19, pp. 1771-1780

DOI: 10.1056/nejmoa1404231

Field-Weighted Citation Impact: 63.98